Clinical Trial

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A multicenter, randomized, open, parallel-designed Phase II study to evaluate the efficacy and safety of HRS-5635 injection alone or in combination with other agents in patients treated for chronic hepatitis B.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-05-17; most recent amendment 2025-11-14.
Status change: Not Yet Recruiting → Recruiting 2024-06-21
Trial Details
NCT Number NCT06425341
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Chronic Hepatitis B
Enrollment 369 participants
Start Date 2024-06-06
Primary Completion 2026-08-30 (estimated)
Study Completion 2027-01-19 (estimated)
Updated on ClinicalTrials.gov 2025-11-17